Aurinia Pharmaceuticals (FRA:IKAP) Net Change in Cash : €33.1 Mil (TTM As of Dec. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Aurinia Pharmaceuticals Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Aurinia Pharmaceuticals's Net Change in Cash for the three months ended in Dec. 2024 was €44.2 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 was €33.1 Mil.

Aurinia Pharmaceuticals Net Change in Cash Historical Data

The historical data trend for Aurinia Pharmaceuticals's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurinia Pharmaceuticals Net Change in Cash Chart

Aurinia Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Change in Cash

Get a 7-Day Free Trial

-27.68

-35.80

-130.02

-41.54

33.00

Aurinia Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Change in Cash	Get a 7-Day Free Trial															2.27	14.34	-28.85	3.37	44.21

Aurinia Pharmaceuticals Net Change in Cash Calculation

Aurinia Pharmaceuticals's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	42.391	+	37.495	+	-46.883	+	0
	=	33.0

Aurinia Pharmaceuticals's Net Change in Cash for the quarter that ended in Dec. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 28.759 + 37.458 + -22.009 + 0

= 44.2

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €33.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurinia Pharmaceuticals Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Aurinia Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (FRA:IKAP) » Definitions » Net Change in Cash

Comparable Companies

VRDN INVA SNDX IOVA NVAX ADPT WVE LQDA MDXG ETNB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270

Traded in Other Exchanges

AUPH:USA

Address

14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6

Website

https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Aurinia Pharmaceuticals Headlines

No Headlines